Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?

Affiliations

¹ Department of Cardiology, University of Rennes, CHU Rennes, INSERM, F-35033 Rennes, France. Electronic address: erwan.donal@chu-rennes.fr.
² Department of Cardiology, University of Rennes, CHU Rennes, INSERM, F-35033 Rennes, France.
³ Department of Pharmacology, Toxicology, and Clinical Pharmacology, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Comment

Erwan Donal et al. Lancet. 2024.

. 2024 Apr 27;403(10437):1604-1606.

doi: 10.1016/S0140-6736(24)00653-6. Epub 2024 Apr 7.

¹ Department of Cardiology, University of Rennes, CHU Rennes, INSERM, F-35033 Rennes, France. Electronic address: erwan.donal@chu-rennes.fr.
² Department of Cardiology, University of Rennes, CHU Rennes, INSERM, F-35033 Rennes, France.
³ Department of Pharmacology, Toxicology, and Clinical Pharmacology, Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

No abstract available

Comment on

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrøm SZ, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Verma S, Einfeldt MN, Lindegaard ML, Rasmussen S, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN; STEP-HFpEF Trial Committees and Investigators. Butler J, et al. Lancet. 2024 Apr 27;403(10437):1635-1648. doi: 10.1016/S0140-6736(24)00469-0. Epub 2024 Apr 7. Lancet. 2024. PMID: 38599221 Free PMC article. Clinical Trial.